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Renal 25-hydroxyvitamin D3-1-hydroxylase in patients with renal dis-
ease. Renal 25-hydroxyvitamin D3-l-hydroxylase (1-hydroxylase) activ-
ity has been measured in 20 patients with renal disease using the
remaining portion of needle renal biopsy specimens taken for diagnostic
purposes and in five patients using kidney tissue removed during
transplantation. The 1-hydroxylase activity of 12 patients with asymp-
tomatic proteinuria and/or hematuria (group A) measured 83.2 37.7
pg/mg tissue/20 mm. Since these 12 patients did not show impaired
mineral metabolism or pathological changes in the renal tubules, we
have presumed that these results indicate normal activity in man. We
also measured the 1-hydroxylase activity in four patients treated with
prednisolone (group B). The 1-hydroxylase activity (81.1 27.1 pg/mg
tissue/20 mm) of group B did not differ from that of group A. However,
the urinary excretion of calcium (ratio of calcium/creatinine) was
increased (0.18 0.07 vs. 0.07 0.03, P < 0.01) by prednisolone
therapy. These data suggest that glucocorticoid-induced changes in
urinary calcium excretion are not the result of a direct effect of
glucocorticoid on renal 1-hydroxylase. In the three patients with mild
renal insufficiency (group C), the 1-hydroxylase activity (75.4 22.4
pg/mg tissue/20 mm) did not differ from that of group A. However, in
five patients with severe renal insufficiency (group D), the 1-hydrox-
ylase activity (8,5 3.7 pg/mg tissue/20 mm) was significantly de-
creased (P C 0.01).
Vitamin D undergoes sequential 25-hydroxylation in the liver
and 1-hydroxylation in the kidney to become an active form that
regulates calcium and phosphorus metabolism [1]. 25-Hydroxy-
vitamin D3- 1 -hydroxylase (1-hydroxylase) has been studied
extensively in avian kidneys because the existence of 25-
hydroxyvitamin D3 (25-OH-D3) binding protein in mammalian
kidney reduces the availability of substrate to the enzyme [2, 3].
Recently, 1-hydroxylase activity was detected in mammalian
kidney homogenate [4], mitochondria [5], isolated cells [6], and
slices [7]. These preparations required extensive washing with
buffer to eliminate the inhibitor. Since these methods require a
relatively large amount of kidney tissue to detect the I -hydrox-
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ylase activity, they were not applicable to small biopsy speci-
mens. Tanaka and DeLuca [81 have developed a technique for
the measurement of mammalian renal 1-hydroxylase activity
that uses substantial amounts of non-radioactive 25-OH-D3
substrate to saturate the inhibitor protein. More recently, we
have developed a micro assay modification of that method for
use with small biopsy specimens for clinical use [9].
In patients with renal disease, vitamin D and mineral metab-
olism may be impaired by the reduction of nephron mass and
the effects of the administration of some drugs. Although serum
levels of 1 ,25-(OH)2D have been studied in patients with renal
disease, l-hydroxylase activity has not been measured. In this
study we have measured 1-hydroxylase activity in patients with
asymptomatic proteinuria and/or hematuria, in patients treated
with prednisolone, and in patients with mild or severe renal
insufficiency.
Methods
As shown in Table 1, we measured 1-hydroxylase activity in
12 patients with asymptomatic proteinuria and/or hematuria
(group A, normal renal function), four patients taking prednis-
olone therapy (group B, normal renal function, two had lupus
nephropathy and the other had idiopathic nephrotic syndrome),
three patients with mild renal insufficiency (group C, glomerular
filtration rate (GFR); 50 to 70 ml/min/l .73 m2), and four patients
with severe renal insufficiency on chronic hemodialysis or
continuous ambulatory peritoneal dialysis (CAPD; group D).
The GFR in another patient of group D was 3.5 ml/min/l.73 m2.
The patients of group A had not received any agents that affect
calcium or phosphorus metabolism. The patients of group B
were being treated with 15 to 20 mg of prednisolone daily at
renal biopsy and had been treated with prednisolone for 45 to
105 days before biopsy. The four patients of group D on
hemodialysis or CAPD had been treated with 1-hydroxyvitamin
D5 (l.OH-D3) until one day before renal transplantation for
prophylaxis of renal osteodystrophy. Except in group D, the
kidney specimens were obtained by an ultrasound-guided nee-
dle biopsy of the lower pole of the kidney. In the five patients
with severe renal insufficiency, 200 to 400 mg of kidney speci-
men was obtained from the outer layer during kidney transplan-
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Table 1. Clinical findings in patients
Case
no.
Age
(year) Sex
Urinalysis
RBC/HPF Protein
Group A 1
2
3
4
5
6
7
8
9
10
11
12
11
9
8
9
10
7
12
14
13
10
15
15
M
F
F
M
F
F
F
F
F
M
F
M
10—20
20—30
2—3
30—40
20—30
>100
10—15
—
90—100
>100
>100
10—20
+
+
2+
+
+
2+
+
+
—
+
Group B
GroupC
13
14
15
16
17
18
19
14
17
14
16
22
7
9
F
F
F
F
M
M
M
2—3
—
—
—
—
2—3
10—20
—
—
—
+
2+
+
+
GroupD 20
21
22
23
24
11
5
12
10
13
M
M
M
F
M
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
Abbreviations are:
not determined.
RBC/HPF, red blood cell/high power field; ND,
tation. The parents of all children had given their informed
consent for renal biopsy.
Blood samples were obtained in the fasting state for serum
analysis and determination of renal function. Serum calcium
[10], inorganic phosphorus [11], and creatinine [12] levels were
determined by automated methods. Urinary calcium, phospho-
rus, and creatinine were determined by an autoanalyzer from a
twenty-four hour collection. The creatinine clearance, cor-
rected for 1.73 m2, was used to express the GFR. The tubular
threshold for phosphate (Tmp/GFR) was determined on the
morning of the serum analyses and derived according to the
Bijvoet nomogram [13].
The biopsy specimen was placed in a petri dish with ice-cold
15 mM Tris-acetate buffer (pH 7.4 at room temperature) con-
taining 0.19 M sucrose, 2 mM EGTA, and 2 mivi dithiothreitol
(DTT). It was examined directly by a stereomicroscopy. Since
the medulla had a parallel linear striated appearance and the
cortex had a tortuous structure, the cortex was easily distin-
guished from medulla. In this study, we did not use specimens
that contained the medulla or the cortical-medullary junction.
The cortical specimen was divided into two portions for histo-
logical analysis and enzyme assay. After blotting the excess
water by paper, the specimen for enzyme assay was placed in a
preweighed aluminum foil boat containing a small amount of the
same buffer. The weight without the specimen was subtracted
from the weight with the specimen. A 2.5% (wt/vol) homoge-
nate was prepared in the same buffer using a micro grinder
(American Scientific Products, McGraw Park, Illinois, USA). A
75 msi succinate solution was also prepared in the same buffer.
The homogenate and the succinate solution were divided into
two test tubes. The succinate solution was always added to the
homogenate in an amount equal to one-half the volume of the
homogenate. The test tubes were placed in a water bath shaker
at 37°C and reaction was initiated by the addition of 25-OH-D3
dissolved in 95% ethanol (1 g of 25-OH-D3/mg tissue/id of 95%
ethanol). A control was always run in which 1 l of 95%
ethanollmg tissue was added to a comparable tube. In severe
renal insufficiency, the functional tubules might not be evenly
distributed in the cortex. To get a representative sample, more
than 100 mg of kidney tissue was homogenized and then one ml
of homogenate per tube (25 mg per tube) was used for the
enzyme assay. We assumed that the 1-hydroxylase activity
measured by this method represented the 1-hydroxylase activ-
ity of the kidney. Incubation was carried out at 37°C with
shaking at 100 oscillations/mm for 20 minutes. The reaction was
terminated by the addition of five volumes of methylene chlo-
ride. Next, 5000 dpm of l,25-(OH)2-[3H]D3 dissolved in 20 d of
95% ethanol was added to the assay tubes to monitor recovery
of 1 ,25-(OH)2-D3 through extraction and chromatography. The
mixture was vigorously vortexed and methylene chloride layer
was then carefully removed with a syringe. The remaining
aqueous phase was re-extracted twice with the same volume of
methylene chloride. The combined methylene chloride extracts
from a total of three extractions were evaporated under nitro-
gen and the residue dissolved in 10% 2-propanol in hexane.
Separation of 1 ,25-(OH)2-D3 was carried out by high perform-
ance liquid chromatography with a Model LC-3A Chromato-
graph (Shimazu Corp., Kyoto, Japan) equipped with a 4.5 mm
x 25 cm Zorbax-Sil column (Dupont, Wilmington, Delaware,
USA) and a 254 nm UV absorbance detector. Chromatography
was carried out with 10% 2-propanol in hexane at 30 kg/cm2 and
a flow rate of 2 mllmin. The elution fraction containing
1 ,25-(OH)2D3 was collected, dried under nitrogen, and dis-
solved in 500 .tI of 95% ethanol. One aliquot was used for
determination of [3H] to calculate recovery of I ,25-(OH)2D3.
Duplicate aliquots were assayed for 1 ,25-(OH)2D3, which was
measured by competitive protein binding assay [14], using
chicken duodenal cytosol (Yamasa I ,25-(OH)2D3 receptor [15];
Yamasa Shoyu Co., Japan) as the binding protein. The intra-
assay coefficient of variation was 7.1%, the inter-assay coeffi-
cient of variation was 14.8%, and the sensitivity was 2 pg/tube.
The apparent l,25-(OH)2D3 detected in the tubes incubated
without substrate was subtracted from the value determined
with samples incubated with substrate.
Renal 1-hydroxylase activity was measured in pig prepara-
tions. Pig kidney was removed from immature (60 lb.) pigs and
placed in the same ice-cold buffer as described above. The
specimens were taken from the outer layer of the kidney. The
enzyme assay was performed as described above.
Data are presented as mean SD. Wilcoxon rank test was
used to compare differences between values obtained.
Results
The production of 1 ,25-(OH)2D3 is linearly related to the
weight of the pig kidney specimen (Fig. 1; r = 0.988, P <0.01).
The weight of kidney tissue of the patients used per tube ranged
from 1.5 mg to 4.3 mg in groups A, B, and C, respectively.
The clinical description of the patients is shown in Table 1,
while the laboratory findings are shown in Table 2.
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Fig. 1. The correlation between the production of I,25-(OH)2D3 and
wet pig kidney weight.
Group A
The stature and body weight were within normal range (data
not shown). Serum level of calcium, inorganic phosphorus,
25-OH-D and 1,25-(014)20 ranged from 8.6 to 9.8 mg/dl (age
matched control: 8.6 to 9.8 mg/dl), 4.0 to 5.5 mg/dl (age matched
control: 3.9 to 5.5 mg/dl), 12.3 to 30.1 ng/ml (normal children:
8.0 to 36.1 ng/ml [14]), and 29.2 to 80.0 pg/mI (normal children:
19.9 to 80.4 pg/mI [14]) were within the normal range, suggest-
ing no evidence of impaired mineral metabolism. Normal GFR
suggests that there had been no impairment of renal function in
these patients (Table 2). Histological study by light microscopy
showed the tubules were normal in these cases (Table 3). Their
renal 1-hydroxylase activity measured 83.2 37.7 pg/mg tis-
sue/20 mm (Fig. 2).
Group B
Normal GFR suggests that there was no impairment of renal
function. Serum concentration of calcium and phosphorus, and
Tmp/GFR were also in the normal range. On the other hand, the
ratio of urinary calcium/creatinine (0.18 0.07 vs. 0.07 0.03,
Pc 0.01) and the serum level of 25-OH-D (10.5 2.2 ng/ml vs.
18.9 6.1 ng/ml, P < 0.05) were significantly different from
those of group A (Table 2). Histological study by light micros-
copy showed that the tubules were normal (Table 3). The
1-hydroxylase activity did not differ from that of group A (Fig.
2).
Group C
The mean OFR was significantly lower (65.1 6.1 vs. 105.6
14.5 ml/min/l.73 m2, P C 0.05) than those of group A. Serum
concentration of calcium and inorganic phosphorus did not
differ from those of group A. Serum levels of 25-OH-I) and
l,25-(OH)2flwere 12.8 2.8ng/mland77.9 4.1 pg/mlanddid
not differ from those of group A. On the other hand, Tmp/GFR
in group C was significantly lower (3.45 0.43 vs. 4.30 0.45
mg/dl 100 ml OF, P C 0.05) than that of group A (Table 2).
Histological study by light microscopy showed there was focal
atrophy in the tubules (Table 3). The l-hydroxylase activity did
not differ from that of group A (Fig. 2).
Group D
The histological study of group D showed end-stage kidney
failure including extensive tubular atrophy (Table 3). The renal
1-hydroxylase activity (8.5 3.7 pg/mg tissue/20 mm) was
significantly lower (P < 0.01) than that of both groups A and C
(Fig. 2). Although serum level of calcium and 25-OH-D did not
differ from group A, serum levels of phosphorus (8.1 1.5
mg/dl vs. 4.7 0.4 mg/dl, P <0.01) and l,25-(OH)2D (41.4
18.3 pg/mI vs. 66.5 19.5 pg/mI, P C 0.05) were significantly
different from those of group A (Table 2). The serum level of
calcium, phosphorus, 25-OH-I), and 1 ,25-(OH)2D in another
end-stage renal failure patient not treated with 1-OH-I)3 was 6.4
mg/dl, 9.2 mg/dl, 21.5 ng/ml, and 19.5 pg/mi, respectively. The
l-hydroxylase activity of this patient was 13.6 pg/mg tissue/20
mm.
Discussion
Recently, Brown and DeLuca reported [16] that l0-oxo-l9-
nor-25-OH-D3 exactly coelutes with 1 ,25-(OH)2D3 on normal
phase HPLC using the same system used in this study. The
presence of this compound in the sample could interfere with
the enzyme assay by binding to the receptor for 1 ,25-(OH)2D3
[16]. However, Okabe et al reported [17] that the 10-oxo-19-
nor-25-OH-D3 does not bind specifically to the receptor for
1,25-(OH)2D3. Brown and DeLuca [161 also indicated that
lO-oxo-l9-nor-25-OH-D is not formed in significant amounts in
incubations of intact mitochondria. Also, using this assay
system neither 10-oxo-19-nor-25-OH-D3 nor 1,25-(OH)2D3 were
detected in preparations from thyroparathyroidectomized rats
[9]. Thus, it is quite unlikely that lO-oxo-l9-nor-25-OH-D3 is
formed or detected by our assay system.
The l-hydroxylase activity in patients with asymptomatic
proteinuria and/or hematuria (group A) was 83.2 37.7 pg/mg
tissue/20 mm. Since these patients did not show impaired
mineral metabolism or pathological change in renal tubules
where the 1-hydroxylase is found, we assume that these results
represent normal values of renal 1-hydroxylase activity in
children. In addition, the l-hydroxylase activity from normal
five-month-old rats is 53.1 21 pg/mg tissue/20 mm [91; our
results from the patients of group A are also in accord with
these values.
It has been suggested that glucocorticoid-induced alterations
in calcium metabolism are responsible for the decrease in
intestinal calcium absorption produced by glucocorticoid ex-
cess. However, the reported results are contradictory. Initial
studies showed a glucocorticoid-induced decrease in both se-
rum 25-OH-D [18] and l,25-(OH)2D [191, but more recent work
has shown that 25-OH-I) is normal [20] and that 1 ,25-(OH)2D is
elevated [21] or unchanged [221. Using a primary monolayer
culture of mouse kidney epithelial cells, Fukase et al [231
r 0.988
Pc 0.01
4.0 8.0 12.0 16.0
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Table 2. Laboratory findingsa
Group A Group B Group C Group D
GFR ml/minll.73 m2 105.6 14.5 110.8 20.3 65.1 6.1" NDd
Blood
Calcium mg/dl
Phosphorus mg/dl
25-OH-D ng/ml
1,25-(OH)2D pg/mI
Tmp/GFR mg/dl 100 GF
9.2 0.4
4.7 0.5
18.9 6.1
66.5 19.5
4.03 0.45
9.1 0.8
4.3 1.0
10.5 2.2"
53.8 12.3
4.00 0.71
9.0 0.7
4.6 1.0
12.8 2.8
77.9 4.1
3.45 0.43"
8.7 1.4
8.1 1.5'
21.9 6.3
41.4 183b
ND
Urine
Calcium/creatinine 0.07 0.03 0.18 0.07" 0.08 0.08 ND
Abbreviations are: GFR, glomerular filtration rate; Tmp/GFR, renal threshold of phosphorus; ND, not determined.
Values are the mean SD.
"Significantly different (P <0.05) from the value in group A.
C Significantly different (P < 0.01) from the value in group A.d The GFR of case no. 24 showed 3.5 ml/minll .73 m2.
Table 3. Histological findings
Group A
Minor glomerular abnormalities with normal tubules
Focal GN with normal tubules
Diffuse mesangial proliferative GN with normal tubules
Membranous GN with normal tubules
Group B
Minor glomerular abnormalities with normal tubules
Diffuse mesangial proliferative GN with normal tubules
Group C
Diffuse mesangial proliferative GN with global sclerosis (50—
57%) and focal tubular atrophy
Group D
End stage kidney with extensive tubular atrophy
reported that physiological concentrations of hydrocortisone
directly stimulate renal 1-hydroxylase activity. In the present
study, the value of the 1-hydroxylase activity in the group
treated with prednisolone did not differ from the group not
treated with prednisolone, whereas the urinary excretion of
calcium (the ratio of calcium/creatinine) was increased and
Tmp/GFR remained unchanged. Thus, glucocorticoids at this
level apparently do not affect the l-hydroxylase while never-
theless altering creatinine/calcium ratio in the urine.
Considering the reduction of nephron mass in chronic renal
disease, it could be anticipated that the 1-hydroxylase activity
would fall. Recent studies have shown that serum l,25-(OH)2D
concentrations fall with moderate and severe renal insufficiency
[24, 251. No information has been available, however, to
indicate at what level of renal insufficiency 1-hydroxylase
activity begins to fall. We have found that 1-hydroxylase
activity is not reduced in mild renal insufficiency (GFR; 65.1
6.1 ml/min/l.73 m2) but that it is reduced in severe renal
insufficiency. Recently, Portale et al [261 have reported that in
children with moderate renal insufficiency (creatinine clear-
ance; 45.4 4, mean SE), a normal dietary intake of
phosphorus is attended by a greatly increased FEPi, reflecting
an increased rate of phosphorus excretion per nephron. It is
possible that an increased intracellular concentration of phos-
phorus in the proximal tubules suppresses the activity of
1-hydroxylase even in the absence of an increased serum level
of phosphorus. An increased serum level of parathyroid hor-
mone in mild renal insufficiency may be expected to stimulate
GroupA GroupB GroupC GroupD
Fig. 2. The renal 25-hydroxyvitamin D3-I-hydroxylase activity in pa-
tients with asymptomatic proteinuria and/or hematuria (group A), in
patients treated with prednisolone (group B), in patients with mild renal
insufficiency (group C), and in patients with severe renal insufficiency
(group D). Results are mean SD. Abbreviation for 25-hydroxyvitamin
D3- 1-hydroxylase is 1-hydroxylase.
1-hydroxylase activity. Therefore, the 1-hydroxylase activity
might be unchanged as a result of two opposite factors.
The renal 1-hydroxylase activity is suppressed by 1,25-
(OH)2D3 and phosphorus [27]. The four patients in group D had
been treated with l-OH-D3, which could be converted in vivo to
l,25-(OH)2D3. But the serum level of l,25-(OH)2D in these
patients was significantly lower than that of group A (Table 2).
Furthermore, the 1-hydroxylase activity in an end-stage renal
failure patient not treated with 1-OH-D3 was also found sup-
pressed. These data indicate that suppression of 1-hydroxylase
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activity in group D was not caused by treatment with 1-OH-D3.
The serum level of phosphorus of the patients in group D was
significantly higher than that in group A (Table 2). In severe
renal insufficiency, therefore, the 1-hydroxylase activity seems
to be reduced by the combination of an increased serum level of
phosphorus and a markedly reduced nephron mass. These
factors apparently are not compensated by an increased serum
level of parathyroid hormone.
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